16-mer hypocretin-1/orexin-A in cerebrospinal fluid to diagnose narcolepsy
The 16-mer orexin-A peptide represents a promising biomarker that could in the future help in the diagnosis of central hypersomnolence disorders. The transition from RIA to LC-MS methods for the quantification of 16-mer orexin-A represents a critical advance toward improving diagnostic accuracy and understanding orexinergic dysfunction in sleep disorders.
Authors
- Catherine Paul (ORCID: https://orcid.org/0000-0002-7657-5535)
- Christophe Hirtz (ORCID: https://orcid.org/0000-0002-7313-0629)
- Valérie Jérôme (ORCID: https://orcid.org/0000-0001-6492-2168)
- Lucie Barateau (ORCID: https://orcid.org/0000-0002-6620-5127)
- Isabelle Jaussent (ORCID: https://orcid.org/0000-0002-8205-7590)
- Yves A Dauvilliers (ORCID: https://orcid.org/0000-0003-0683-6506)
- Manuela Lotierzo (ORCID: https://orcid.org/0000-0002-7555-5129)
- Tanty Jerome
- Sylvain Lehmann (ORCID: https://orcid.org/0000-0001-6117-562X)
Institutions
- Inserm (FR)
- Université de Montpellier (FR)
- Centre Hospitalier Universitaire de Montpellier (FR)
- Hôpital Gui de Chauliac (FR)
- Laboratoire National de Référence (MA)
- Hôpital Lapeyronie (FR)
- Institute for Neurosciences of Montpellier (FR)
- Laboratoire de Synthèse Organique (FR)
Publication Details
- Journal
- SLEEP
- Published
- 2025-08-12
- DOI
- https://doi.org/10.1093/sleep/zsaf237
- Citations
- 3
- Primary Topic
- Sleep and Wakefulness Research
- Type
- article
- Field-Weighted Citation Impact
- 4.29